EVH

SEC source: 0001628908-23-000185 · wk-form4_1701899379.xml · nonDerivative · entry 1

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 778,645

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of the leveraged stock units ("LSUs") granted to Mr. Blackley on June 4, 2020, based on the cumulative performance of the Issuer's Class A Common Stock.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

F3 · balance_after: Since the date of the reporting person's last ownership report, Mr. Blackley transferred 284,366 shares of Evolent Health, Inc. Class A Common Stock pursuant to a domestic relations order.

SEC source: 0001628908-23-000178 · wk-form4_1700485254.xml · derivative · entry 5

McCarthy Daniel Joseph · CIK 0001946147 · PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 3,000 shares

Expires 2025-05-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2023.

F3 · derivative.exercise_date: The Class A Common Stock Options exercised vested on May 12, 2019.

SEC source: 0001628908-23-000178 · wk-form4_1700485254.xml · nonDerivative · entry 4

McCarthy Daniel Joseph · CIK 0001946147 · PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 198,333

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2023.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000178 · wk-form4_1700485254.xml · nonDerivative · entry 3

McCarthy Daniel Joseph · CIK 0001946147 · PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 201,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2023.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000178 · wk-form4_1700485254.xml · nonDerivative · entry 2

McCarthy Daniel Joseph · CIK 0001946147 · PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 198,333

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2023.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000178 · wk-form4_1700485254.xml · nonDerivative · entry 1

McCarthy Daniel Joseph · CIK 0001946147 · PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 202,333

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2023.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000143 · wf-form4_169636544693379.xml · nonDerivative · entry 1

Rafferty Emily Ann · CIK 0001983577 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,407

F1 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000132 · wf-form4_169230454251236.xml · nonDerivative · entry 1

Rafferty Emily Ann · CIK 0001983577 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,897

F1 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 3 previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000127 · wf-form4_169109535664870.xml · nonDerivative · entry 1

Shams Aammaad · CIK 0001815354 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,024

F1 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000125 · wf-form4_169109524134661.xml · nonDerivative · entry 1

Ajayi Toyin · CIK 0001988404 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,386

F1 · security: Represents restricted stock units granted to Dr. Ajayi pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of August 1, 2024 and the date of the Company's 2024 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-24-000044 · wk-form4_1714161825.xml · nonDerivative · entry 1

Tutewohl Steve · CIK 0001811845 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,331

F1 · security: This Form 4 is being filed late due to an administrative error.

F2 · shares: Represents restricted stock units granted to Mr. Tutewohl pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. On July 31, 2023, Mr. Tutewohl's last day of employment with the company, 3,000 of these RSUs vested and the remaining 6,000 were forfeited, in accordance with the terms of Mr. Tutewohl's severance and change in control agreement. Mr. Tutewohl ceased to be an officer of the company on July 3, 2023.

F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000107 · wf-form4_168815682764495.xml · derivative · entry 4

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 33,011 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.

F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2017.

SEC source: 0001628908-23-000107 · wf-form4_168815682764495.xml · nonDerivative · entry 3

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 783,011

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.02 to $31.30, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000107 · wf-form4_168815682764495.xml · nonDerivative · entry 2

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 791,480

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.02 to $31.01, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000107 · wf-form4_168815682764495.xml · nonDerivative · entry 1

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 816,022

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000105 · wf-form4_168729338294086.xml · derivative · entry 6

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,011

Underlying: Class A Common Stock · 2,098 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.

F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2017.

SEC source: 0001628908-23-000105 · wf-form4_168729338294086.xml · nonDerivative · entry 4

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 783,011

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.09 to $30.16, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000105 · wf-form4_168729338294086.xml · nonDerivative · entry 3

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 785,109

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000105 · wf-form4_168729338294086.xml · derivative · entry 5

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,109

Underlying: Class A Common Stock · 75,931 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.

F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2017.

SEC source: 0001628908-23-000105 · wf-form4_168729338294086.xml · nonDerivative · entry 2

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 783,011

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.52, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000105 · wf-form4_168729338294086.xml · nonDerivative · entry 1

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 858,942

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2023.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000103 · wf-form4_168694791322139.xml · nonDerivative · entry 1

Scott Cheryl · CIK 0001656979 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,788

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.03, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000101 · wf-form4_168686065872798.xml · nonDerivative · entry 1

DUFFY MARY BRIDGET · CIK 0001570881 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,935

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.77 to $31.24, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000099 · wf-form4_168677667580018.xml · nonDerivative · entry 1

Holder Diane · CIK 0001642976 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,140

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.11 to $31.54, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000097 · wf-form4_168677649186474.xml · nonDerivative · entry 1

McCarthy Daniel Joseph · CIK 0001946147 · PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 206,333

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2023.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000090 · wf-form4_168660497370924.xml · nonDerivative · entry 1

KECK KIM · CIK 0001818332 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,273

F1 · security: Represents restricted stock units granted to Ms. Keck pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 8, 2024 and the date of the Company's 2024 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-23-000096 · wf-form4_168662060611901.xml · nonDerivative · entry 1

Jelinek Richard M · CIK 0001707429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,749

F1 · security: Represents restricted stock units granted to Mr. Jelinek pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 8, 2024 and the date of the Company's 2024 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-23-000089 · wf-form4_168660495656923.xml · nonDerivative · entry 1

Holder Diane · CIK 0001642976 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,140

F1 · security: Represents restricted stock units granted to Ms. Holder pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 8, 2024 and the date of the Company's 2024 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-23-000085 · wf-form4_168660483831009.xml · nonDerivative · entry 1

GRUA PETER J · CIK 0001242813 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,668

F1 · security: Represents restricted stock units granted to Mr. Grua pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 8, 2024 and the date of the Company's 2024 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-23-000087 · wf-form4_168660492615314.xml · nonDerivative · entry 1

Barbarosh Craig A. · CIK 0001472457 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,247

F1 · security: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 8, 2024 and the date of the Company's 2024 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-23-000091 · wf-form4_168660498858162.xml · nonDerivative · entry 1

DUFFY MARY BRIDGET · CIK 0001570881 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,499

F1 · security: Represents restricted stock units granted to Dr. Duffy pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 8, 2024 and the date of the Company's 2024 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-23-000088 · wf-form4_168660493913510.xml · nonDerivative · entry 1

Sotunde Tunde · CIK 0001891237 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,018

F1 · security: Represents restricted stock units granted to Dr. Sotunde pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 8, 2024 and the date of the Company's 2024 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-23-000086 · wf-form4_168660488009803.xml · nonDerivative · entry 1

Scott Cheryl · CIK 0001656979 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,153

F1 · security: Represents restricted stock units granted to Ms. Scott pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 8, 2024 and the date of the Company's 2024 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-23-000072 · wf-form4_168599661662369.xml · derivative · entry 9

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,250

Underlying: Class A Common Stock · 90,940 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F9 · derivative.exercise_date: The Class A Common Stock Options exercised vested on March 1, 2017, March 1, 2018, March 1, 2019, and March 1, 2020.

SEC source: 0001628908-23-000072 · wf-form4_168599661662369.xml · derivative · entry 8

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 19,060 shares

Expires 2025-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F8 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2019.

SEC source: 0001628908-23-000072 · wf-form4_168599661662369.xml · nonDerivative · entry 6

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 819,812

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.60 to $29.86, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000072 · wf-form4_168599661662369.xml · nonDerivative · entry 5

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 868,838

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.60 to $29.59, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000072 · wf-form4_168599661662369.xml · nonDerivative · entry 4

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 910,752

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.63 to $29.83, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000072 · wf-form4_168599661662369.xml · nonDerivative · entry 3

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 920,721

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.63 to $29.62, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000072 · wf-form4_168599661662369.xml · nonDerivative · entry 2

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 929,812

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000072 · wf-form4_168599661662369.xml · nonDerivative · entry 1

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 838,872

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000063 · wf-form4_168314547129704.xml · derivative · entry 4

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,060

Underlying: Class A Common Stock · 110,000 shares

Expires 2025-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2019.

SEC source: 0001628908-23-000063 · wf-form4_168314547129704.xml · nonDerivative · entry 2

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 819,812

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.79 to $36.68, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000063 · wf-form4_168314547129704.xml · nonDerivative · entry 1

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 929,812

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000053 · wf-form4_168072741293449.xml · derivative · entry 5

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,060

Underlying: Class A Common Stock · 110,000 shares

Expires 2025-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2018 and February 1, 2019.

SEC source: 0001628908-23-000053 · wf-form4_168072741293449.xml · nonDerivative · entry 3

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 819,812

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.14 to $32.57, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000053 · wf-form4_168072741293449.xml · nonDerivative · entry 2

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 825,686

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.138 to $32.135, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000053 · wf-form4_168072741293449.xml · nonDerivative · entry 1

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 929,812

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000045 · wf-form4_167823026516991.xml · nonDerivative · entry 4

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 819,812

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2022.

F4 · shares: This number represents shares of Class A Common Stock sold to satisfy the tax withholding obligation due upon vesting of LSUs.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.35 to $34.92, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-23-000047 · wf-form4_167823038064797.xml · nonDerivative · entry 4

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 783,011

F3 · shares: This number represents shares of Class A Common Stock sold to satisfy the tax withholding obligation due upon vesting of LSUs.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.35 to $34.92, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.